Phase 3 N=1,717 A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 32.4; 30.2 months — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,053 Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
Diabetes, Type 1 · Diabetes, Type 2
Primary: Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care — -0.16; -0.12 liters
Phase 2 N=18 A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Time to Minimum Endogenous Glucose Production (EGP) - Meal Challenge — 75.0; 75.0; 125.0; 60 Minutes
Phase 3 N=589 Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes
Diabetes, Type I
Primary: Compare the Mean Change From Baseline to Week 52 in HbA1c — -0.13; -0.37 Percentage
Phase 4 N=109 Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
HIV, Combination Therapy
Primary: Percentage of Participants With HIV-1 RNA Level <40 c/mL at Week 24 — 80.6; 94.6 Percentage of participants
Phase 3 N=528 Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue — -0.78; -0.70 Percentage of total hemoglobin — p=0.420
Phase 2 N=229 An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial
Type 2 Diabetes Mellitus
Primary: Annual Rate of Change in FEV1 From Baseline to End of Study — -0.048 Liters per year
N/A N=25 A Study of Tomato Products and Disease Risk
Inflammation
Primary: IL-6 Concentrations — 2.2; 2.6 pg/mL — p=<0.0001
Phase 4 N=249 Catheter Evaluation for Endocardial Ablation in Patients With Ventricular Tachycardia
Ventricular Tachycardia
Primary: The Percentage of Subjects That Expire From All-cause Mortality Within 12-months Post Ablation. — 13.3 percentage of mortality
Phase 2 N=243 Edessy ICSI Outcome Embryo Score (EIOS) Efficacy
Infertility
Primary: Clinical Pregnancy — 71 participants
Phase 2 N=29 A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro
Diabetes Mellitus: Type 1
Primary: Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin AUC0-360 — 3337.2…
N/A N=1,978 Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits
Latent Tuberculosis Infection
Primary: TST Induration Will be Interpreted Relative to Risk, in Accordance With Published CDC Guidelines. — 2; 37; 20 participants
Phase 3 N=412 VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia
Insomnia
Primary: Average Improvement of Latency to Persistent Sleep (LPS) — 45.8; 24.3; 19.6; 23.1 minutes — p=<0.001
Phase 4 N=328 Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
Parkinson's Disease
Primary: Change From Baseline to Week 18 in the Unified Parkinson's Disease Rating Scale (UPDRS) Total Score for Parts I, II and III — -3.6; -1.2 units on a scale — p=0.012
Phase 3 N=322 VEC-162 Study in Adult Patients With Primary Insomnia
Primary Insomnia
Primary: Average Change From Baseline - Latency to Persistent Sleep (LPS) — 45.0; 46.4; 28.3 minutes